Member Info for TR64

The complaint also relies heavily on the way that the company communicated to investors and the general public concerning anomalies in the vaccine’s interim clinical trial results

https://www.dandodiary.com/wp-content/uploads/sites/893/2021/01/AstraZeneca-complaint.pdf

Stille.
I agree 100%

2 more mRNA vaccines to come
NASDAQ CVAC , just raised $450 million to help in manufacture of the small mobile factory units that can produce 100,000 doses a week anywhere in the world, Telsa involved with it. Results due next Month of phase 3 trail
Then the next one in March/April is NASDAQ: ARCT

One more after that, its still in early stage , its another mRNA
NASDAQ: TBIO

US Debt when Trump took office stood at $19.1 trillion when he left it stood at $26.70 trillion
What a T0sser Trump was and still is.

Tax breaks that suited the top 2%.

The vaccine will be for every age.

Plymouth Hospital at Derryford have been part of the trials under Pharmaceutical company, its been trailed successfully on people over 65 and those with underlying conditions, it's showed up well on Diabetics as well

Nice to have another EU Belgium Company wheel out another Vaccine

GSK will take up 1.25 million of the new shares issued by CVAC .
CVAC will use part of the capital to help fund multiple small mobile units that can be erected anywhere in the world in 24 hours.

CVAC is still a good buy at $98.00, expect it will shock a few on its next big announcement

VIR 7381 VIR-7831 Worked well for the early treatment of COVID-19 in patients who are at high risk of hospitalization. VIR-7831 its a JV with GSk where its known as GSK4182136,. So both they are the same developed jointly, each with a number, so both companys can refer to them under there own number.

They took VIR-2482 antibody into trails in the USA in October/November
They then took VIR 7381 into trials in December 16 /2020, with GSK 4182136 Antibody treatment ,this Phase 3 study is part of the National Institutes of Health program in the USA

On December January 12/ 2021
Vir and GSK announced that NHS-supported clinical study on their second coronavirus therapeutic candidate, VIR-7832, and GSK4182136 in the UK National Health Service.

In sumary, they trailed the first antibody and then moved to a phase 3 study in the USA, which one must assume was good results, as VIR and GSK broughit into the NHS

By combining the data from Eli Lilly, and GSK, VIR have now worked with both to combine the antibody further, so there are no 4 Antibody treatments, the last is with Eli Lilly, with the other 3 all doing well

The Phase 3 trail in the USA will come this month, and the UK trail in the NHS will take around a month I assume

Seaking , Legal action when CEO do the wrong things, hence the EU and Pension funds., Not me , try AZN CEO

TA,
Cant price it in GSK sp,
VIR now $138.37
Its now worth $1.65 billion to gsk

VIR $110.32

Detail is in the 10 am release on VIR 7831
Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136

Its partially out today, trading at $96 dollars.

Combined trails with EL, GSK.

Credit Suisse and UK rooks, cant even price in GSK investment of $25o million is now worth $1.2 billion

UK is full of -rooks

One part , but by all means read it all.

The Cambridge-based pharmaceutical company told investors last year that it was making strong progress on developing a coronavirus jab and that it had agreed contracts to deliver 400 million doses.

But experts raised concerns over a lack of data on the jab’s effectiveness on people aged over 55 when the FTSE 100 company revealed its test results in November.

Health officials also raised questions about trial results showing that the jab was only 62pc effective in people who received two full doses but 90pc effective for subjects who were given half a dose followed by a full dose.
Pascal Soriot, Astra’s chief executive, told Italian newspaper La Repubblica on Tuesday that the company’s partners at Oxford University had “said it was not ethical to vaccinate old people until they had enough safety data in younger people”.
https://www.telegraph.co.uk/business/2021/01/27/astrazeneca-sued-pension-fund-alleged-covid-vaccine-testing/

AZN have already trebled the price to South Africa, which WHO picked up and will act, as it goes against everythiung other responsible Pharma companys are doing

INDIANAPOLIS, SAN FRANCISCO and LONDON, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate COVID-19. Lilly has expanded its ongoing BLAZE-4 trial to evaluate the administration of bamlanivimab (LY-CoV555) 700mg with VIR-7831 (also known as GSK4182136) 500mg, two neutralizing antibodies that bind to different epitopes of the SARS-CoV-2 spike protein. This unique collaboration marks the first time that monoclonal antibodies from separate companies will be brought together to explore potential outcomes.

Bamlanivimab is a neutralizing antibody directed against the spike protein of SARS-CoV-2 designed to block viral attachment and entry into human cells, thus neutralizing the virus. Bamlanivimab emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of COVID-19. Bamlanivimab is authorized for emergency use for the treatment of mild to moderate COVID-19 in patients who are at high risk for progressing to severe COVID-19 and/or hospitalization.

VIR-7831 is a dual-action monoclonal antibody that was selected for clinical development based on its potential to both block viral entry into healthy cells and clear infected cells, as well as its potential to provide a high barrier to resistance. In pre-clinical trials, the antibody has shown the ability to neutralize the SARS-CoV-2 live virus by binding to an epitope on SARS-CoV-2 shared with SARS-CoV-1, indicating that the epitope is highly conserved, which may make it more difficult for escape mutants to develop. Vir and GSK are advancing VIR-7831 as part of their collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2.

“Bamlanivimab is a potent antibody – with data from multiple Phase 2 and 3 clinical trials, which have demonstrated robust evidence for both treating and preventing COVID-19,” said Daniel Skovronsky, M.D., Ph.D., Lilly’s chief scientific officer and president of Lilly Research Laboratories. “With a virus like SARS-CoV-2, it’s expected that variants could emerge that require new therapeutic options, which is why Lilly is studying bamlanivimab together with other neutralizing antibodies, including etesevimab. Adding VIR-7831 to our study is an important part of our commitment to develop therapies to treat current and future strains of COVID-19 until vaccines are widely available and utilized.”

“We believe that VIR-7831 has significant potential as a single agent, and we are optimistic about the pending interim data from two Phase 3 trials evaluating its potential for early treatment and in hospitalized patients,” said George Scangos, Ph.D., chief executive officer of Vir.

DMP

The reason can be found and i put it down to this
Shares in Issue
Novartis shares in Issue 2 billion 200 million shares approx

Astra Zenka 1 billion 300 million shares in issue approx

GSK 5 billion 100 million shares in issue approx

Main salient point , Novartis dividend is 2%.
AZN dividend is the same and AZN borrow £ billion to pay such a pathetic dividend

Its how company operate, and pay dividends to share holders, if GSK reduced share in issue, which I doubt they would do, then they would be paying a dividend a lot higher

Key point here is, GSK forms part of long term pension funds , AZN , Novartis dont, they are part of growth funds, with higher degreee of risk

Many pensioners and investors like the %.8% dividend they dont buy the stock for the CEO to take risks and lose money, which means they have to borrow like AZN to pay a dividend

Biontech VACCINE ,Pfizer are the Junior partner.
Of course vaccines efficacy makes a difference and comparing them to telsa cars is childish

Biotechnology AZN cant do, Biontech and 2 others have done, hence why it can be given to people over age 65.

The other and 3rd mRNA vaccine can be stored at room temp and lasts 3 months anywhere in the world, its the one vaccine that will help the world

VIR Antibody Phase 3 trails news to come yet.
VIR Discovery on Hepatitis is huge, especially as Gilead have no interest in this VIR Treatment, but GSK do and the antibody against Covid 19
VIR Closed @$77.38, UP 75% ON THE DAY.

VIR CLOSES @ $76 .30

GSK own 6,75% of the shares, he share rice today increased by 72%, with after market trading to continue for 30 minutes

Great Work by Emma Walmsley and Hal Barron again !!!!!!!

Its at best 62%
The data the MHRA have and produced show 62%

You seem to want to change the MHRA data, of course the vaccine as not even completed its trails in the USA an dhalted them in Brazil

Everyone wants a safe good vaccine, but when you alter data to suit AZN CEO BS comments, it makes it worse.

62% means 38 people in every 100, are not protected.

The EU can take every Euro back from AZN and impose License refusal, its very simple, if you want to play the little britian card, suffer the consequences and that means Biontech Pfizer license wont get approved for export as well to the UK.

Good luck